New XEC COVID Variant On The Rise: What Are Its Symptoms?

As COVID activity remains high in the United States, a new variant called XEC is spreading rapidly in Europe and other parts of the world. Although few cases have been detected in the U.S. so far, experts are projecting that XEC could be on track to become the dominant strain in the country this fall.

The SARS-CoV-2 virus, which causes COVID, is continuing to mutate, giving rise to new, highly contagious variants. The latest one to gain interest and make headlines, the recombinant omicron variant called XEC has sparked recent discourse among scientists on X.

Dr. Eric Topol, physician scientist and director of the Scripps Research Translational Institute, posted on X last week that the "XEC variant appears to be the most likely one to get legs next."

As respiratory virus season approaches in the U.S., some are concerned about whether XEC could cause a fall surge, and if the new COVID-19 vaccines being rolled out will protect against it.

What do we know about the XEC variant so far, what symptoms does it cause, and what can we expect in the coming months?

XEC is a recombinant of two previous variants, KP.3.3 (a FLiRT variant) and KS.1.1, Dr. Albert Ko, an infectious disease physician and professor at Yale School of Public Health, tells TODAY.com.

"When a person's infected with two different SARS-CoV-2 variants, you can get what we call a recombination, where pieces of the genetic material from one recombine with the other, and that can create a new strain," says Ko.

The XEC variant is a sublineage of omicron, just like the previous variants that have been circulating in recent months, Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, tells TODAY.com.

These include the FLiRT strains and the currently-dominant variant in the U.S., KP.3.1.1, which some scientists have dubbed “DeFLuQE.”

According to Mike Honey, an Australian data scientist who has been tracking XEC’s spread, the variant first emerged in Berlin in late June and has since rapidly spread in Europe, North America and Asia, Honey wrote in a post on X on Sept. 14.

XEC is showing the "strongest growth" in Germany and Denmark, Honey added, and is spreading rapidly in a number of other places. XEC has been reported in at least 27 countries so far.

In the U.S., at least 95 cases have been reported across 12 states so far, according to the latest data from Scripps Research's COVID-19 database, Outbreak.info.

"It's definitely here but it hasn’t made it to the CDC tracker because not enough cases have been detected," says Ko. XEC is not yet listed on the U.S. Centers for Disease Control and Prevention "Nowcast" estimates, which project COVID variant proportions in the U.S. for the most recent two-week period.

However, this is expected to change. According to Honey, XEC "looks a likely next challenger against the now-dominant DeFLuQE variants," he wrote in a post on X on Sept. 14.

"(XEC) appears to be, like many of the other Omicron variants we have seen recently, quite contagious (and) very easily spread, which is why it's picking up steam," says Schaffner.

XEC, like other COVID variants, is spread from person to person through respiratory droplets produced when an infected person breathes, talks, coughs, or sneezes.

"It is rising at a fast rate right now (and) it's the fastest rising variant in a couple different countries in Europe," says Andrew Pekosz, PhD, professor and vice chair of the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, tells TODAY.com.

“Any time a new variant emerges and starts to increase rapidly, we always turn our eyes toward it. ... That is really is the first signal that something might be happening,” says Pekosz.

The XEC variant has at least one mutation in its spike protein, says Pekosz. While this may potentially make it more transmissible, it's unclear whether XEC will outcompete other variants.

"It looks to be behaving the way many of these other omicron subvariants have behaved. So far, no alarm bells have gone off regarding XEC," says Schaffner.

"The 2024 summer wave was more prominent and has been more prolonged than we anticipated. It’s only now starting to wane," says Schaffner.

There is no COVID "season" in the U.S. and activity can continue throughout the year. Cases tends to peak in the winter months during respiratory virus season, the experts note, but can also surge in the spring and summer, per the CDC.

The timing and severity of COVID-19 surges is difficult to predict, says Pekosz, but he speculates that there's a chance this winter wave may come later or not be as big as last year's due to the size of the summer wave, which provided some people immunity. However, it's unclear how the next few months will pan out.

It's also too early to tell whether XEC or another variant will drive a fall or winter surge. "New variants with new mutations come up and some of them take off (and) some of them don't take off," says Ko.

"XEC may be the next one that's going to take off and cause a wave, but we're not sure how big that wave may be," Ko adds.

One thing we do know is respiratory virus season is approaching, and viruses like SARS-CoV-2 and influenza are spread more readily in the winter when people spend time together indoors.

“I can firmly predict that there will be a winter increase. When and how robust that increase will be, I don’t know, but it should have nothing to do with your decision to get vaccinated," Schaffner adds.

It's still early in XEC's emergence, which means there isn't much information yet about its symptoms or other clinical features, says Pekosz. However, so far, XEC does not appear to be causing any distinctive symptoms or more severe disease.

"It's the same old, same old," Schaffner adds. The symptoms caused by XEC are similar to those caused by previous omicron variants. These include:

"It can make you feel miserable for several days, but it can vary from person to person and some people get a totally asymptomatic infection," says Schaffner.

People in high-risk populations are more likely to develop severe disease. These include people over the age of 65, people with underlying medical conditions (such as diabetes or heart disease), and people who are immunocompromised.

“There’s nothing striking (about XEC) both in terms of the symptoms it causes, and also the virulence, or its ability to cause hospitalizations and deaths,” says Ko. So far, XEC seems similar to KP.2 and KP.3, he adds.

The updated COVID-19 vaccine for 2024–2025 is available and recommended by the CDC for everyone ages six months and older.

The new mRNA vaccines are monovalent, which means they target one variant — in this case, it's the previously dominant KP.2 variant, says Pekosz. "It looks like (XEC) is going to be closer related to the vaccine strains, so there should be good coverage," he adds.

“Although it’s new, there have been some early laboratory studies that would indicate that the updated vaccine will protect against severe disease caused by this variant,” Schaffner adds.

COVID-19 vaccines are safe and effective at protecting people from developing severe illness, being hospitalized, and dying, according to the CDC. This means they can still offer protection even if a person becomes sick with COVID-19 after being vaccinated.

The strains targeted by the COVID vaccines are chosen over the summer, about three or four months before the shots become available, Pekosz notes. "While the vaccine strain doesn't change, the virus just keeps infecting people and mutating, so we never have 100% match," he adds.

However, it looks like the current vaccines will provide protection against should the XEC variant spread widely in the U.S. this fall.

"Now (through October) is a good time to get vaccinated," says Ko. If you’ve recently recovered from a COVID-19 infection, the CDC recommends waiting three months to get the vaccine, but always talk to your doctor.

It's especially important for people at higher risk of developing severe disease to get the updated COVID-19 vaccine, says Schaffner. These groups should get vaccinated as soon as possible because the virus is still circulating at relatively high levels around the country, TODAY.com previously reported.

A concern among experts is that poor vaccine uptake will create a more vulnerable population this winter. "We had a rather lackluster acceptance rate last year, only 24% of the population (who was eligible) actually received the vaccine, so I hope we do much better this fall," says Schaffner.

Current COVID-19 tests are expected to detect the XEC variant and other strains in circulation, the experts say.

People should test if they have COVID-19 symptoms or an exposure. It's also a good idea to test ahead of big events or gatherings where you'll be around high-risk individuals, says Schaffner.

The CDC recommends staying home if you're sick and returning to normal activities only if you have been fever-free and symptoms have been improving for at least 24 hours.

Antivirals such as Paxlovid are still effective and recommended, particularly for people at high risk for severe disease, Schaffner notes. These are most effective when taken within the first few days of developing symptoms.

As fall approaches, you can take the following steps to protect yourself from COVID-19 and other respiratory viruses:

Caroline Kee

Caroline Kee is a health reporter at TODAY based in New York City.